Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk
{"title":"PET诊断后肿瘤恶性程度增加的风险","authors":"Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk","doi":"10.2478/cipms-2022-0007","DOIUrl":null,"url":null,"abstract":"Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.","PeriodicalId":11071,"journal":{"name":"Current Issues in Pharmacy and Medical Sciences","volume":"35 1","pages":"34 - 40"},"PeriodicalIF":0.4000,"publicationDate":"2022-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The risk of increasing tumor malignancy after PET diagnosis\",\"authors\":\"Agnieszka Korga-Plewko, Marta Ostrowska-Leśko, Magdalena Iwan, J. Szponar, A. Wróbel, M. Cendrowska-Pinkosz, L. Grzycka-Kowalczyk, E. Poleszak, B. Ślaska, J. Dudka, B. Chrapko, S. Mańdziuk\",\"doi\":\"10.2478/cipms-2022-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.\",\"PeriodicalId\":11071,\"journal\":{\"name\":\"Current Issues in Pharmacy and Medical Sciences\",\"volume\":\"35 1\",\"pages\":\"34 - 40\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Issues in Pharmacy and Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/cipms-2022-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Issues in Pharmacy and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/cipms-2022-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
The risk of increasing tumor malignancy after PET diagnosis
Abstract This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.